2023.6.2
Results from preclinical study were presented by Dr. Juanjuan Ye at American Society of Clinical Oncology (ASCO) annual meeting 2023.
Title: Effect of locoregional injection of RNA oligonucleotide targeting carbohydrate sulfotransferase 15 on both tumoral and lymph node MDSCs and T cell infiltration in pancreatic tumor in mice.
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e16310?af=R
2023.5.30
Results from preclinical study were published by Dr. Juanjuan Ye in European Journal of Immunology.
Title: Silencing of tumoral carbohydrate sulfotransferase 15 reactivates lymph node pancreatic cancer T cells in mice.
https://onlinelibrary.wiley.com/journal/15214141
https://pubmed.ncbi.nlm.nih.gov/37248998/
2022.11.18
The results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were published in the LANCET eClinicalMedicine.
Fujisawa T et al. STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial. The LANCET eClinicalMedicine 2023;55: 101731
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00461-8/fulltext
2022.6.2
Final results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2022.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.4144
2022.6.2
Results from preclinical study were presented by Dr. Ye at American Society of Clinical Oncology (ASCO) annual meeting 2022.
Title: Effect of silencing tumoral carbohydrate sulfotransferase 15 on T cells in a murine model of pancreatic cancer.
https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e16241
2022.5.22
Results from preclinical study were presented by Dr. Ye at Digestive Disease Week (DDW) annual meeting 2022.
Title: Silencing of tumoral carbohydrate sulfotransferase 15 augments tumor-infiltrating T cells with boosted lymph node T cell priming in a murine model of pancreatic cancer
2022.5.21
Final results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tanisaka at Digestive Disease Week (DDW) annual meeting 2022.
Title: Locoregional injection of the RNA oligonucleotide targeting carbohydrate sulfotransferase 15 is able to accelerate tumor-infiltrating T cells in patients with unresectable pancreatic cancer, refractory to first-line chemotherapy
2021.6.4
Top-line results from Phase 1/2a clinical study of STNM01 as a second-line therapy for unresectable pancreatic cancer were presented by Dr. Tsuchiya at American Society of Clinical Oncology (ASCO) annual meeting 2021.
Title: A phase I/IIa trial of the RNA oligonucleotide STNM01 by EUS-FNI to investigate the safety and efficacy in patients with first-line refractory, unresectable pancreatic cancer.
https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.4120
2018.4.26
Results of IIT for unresectable pancreatic cancer was published in GIE.
Nishimura M, et al. Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival in patients with unresectable pancreatic cancer. Gastrointest Endosc. 87:1126-1131, 2018.
2018.3.22
Phase 1/2a IIT program for unresectable pancreatic cancer was adopted by AMED innovative research program.